loading page

SEVERE/REFRACTORY AUTOIMMUNE HEMOLYTİC ANEIMIA İN AN INFANT SUCCESSFULLY TREATED WITH RITUXIMAB
  • +6
  • Fatma Nur Ayman,
  • Murat Elli,
  • Yontem Yaman,
  • Nihan Bayram,
  • Leyla Telhan,
  • Esra Korkmaz,
  • Cengiz Erol,
  • Hülya Bilgen,
  • Sema Anak
Fatma Nur Ayman
Istanbul Medipol Universitesi
Author Profile
Murat Elli
Istanbul Medipol Universitesi
Author Profile
Yontem Yaman
Behcet Uz Children's Hospital
Author Profile
Nihan Bayram
Istanbul Medipol University
Author Profile
Leyla Telhan
Istanbul Medipol Universitesi
Author Profile
Esra Korkmaz
Istanbul Medipol Universitesi
Author Profile
Cengiz Erol
Istanbul Medipol Universitesi
Author Profile
Hülya Bilgen
Istanbul Medipol Universitesi
Author Profile
Sema Anak
Istanbul Medipol Universitesi
Author Profile

Abstract

Autoimmune hemolytic anemia (AIHA) is a rare condition in children which differs from the adult form. It is defined by immune-mediated destruction of red blood cells caused by autoantibodies. Treatment depends on the type of AIHA, its severity and whether there is an underlying disorder. Rituximab is now the preferred second-line treatment for primary warm autoimmune hemolytic anemia (Waiha). Here, we present a 2-monthboy with wAIHA, resistant to steroids and cyclosporin A, who was successfully treated with rituximab. Our patient is one of the youngest cases in the literature.